Last mentioned: 3d ago
Bank of America has raised its price target for Johnson & Johnson (JNJ), citing a strengthened outlook for the company's pharmaceutical and MedTech pipelines. The upgrade reflects growing investor confidence in JNJ's post-Kenvue strategy, which prioritizes high-margin innovation in oncology, immunology, and surgical robotics.
A new DelveInsight report projects a steady 7% CAGR for the minimally invasive surgical devices (MISD) market through 2034, driven by technological leaps in robotics and a global shift toward outpatient care. This expansion reflects a broader healthcare transition prioritizing reduced recovery times and improved clinical outcomes over traditional open surgeries.
A series of recent clinical studies have directly challenged the public health assertions made by Robert F. Kennedy Jr. regarding vaccines, Tylenol, and antidepressants. These findings underscore a growing tension between evidence-based medicine and the policy platform of the potential future leadership at the Department of Health and Human Services.